title: Treatment of facial lipoatrophy with polymethylmethacrylate among patients with human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS): impact on the quality of life.
abstract: BACKGROUND
  The lipodystrophy syndrome is characterized by selective loss of subcutaneous fat on the face and extremities (lipoatrophy) and/or accumulation of fat around the neck, abdomen, and thorax (lipohypertrophy). The aim of this study has been to assess the impact of polymethylmethacrylate facial treatment on quality of life, self-perceived facial image, and the severity of depressive symptoms in patients living with HIV/AIDS.
  
  
  METHODS
  A non-randomized before and after interventional study was developed. Fifty-one patients underwent facial filling. The self-perceived quality of life, facial image, and degree of depressive symptoms were measured by the Short-Form 36 and HIV/AIDS--Targeted quality of life questionnaires, by a visual analogue scale and by the Beck depression inventory, respectively, before and three months after treatment.
  
  
  RESULTS
  Six of the eight domains of Short-Form 36 and eight of the nine dimensions of the HIV/AIDS--Targeted quality of life questionnaires, together with the visual analogue scale and by the Beck depression inventory scores, revealed a statistically significant improvement. The only adverse effects registered were edema and ecchymosis.
  
  
  CONCLUSIONS
  The treatment of facial lipoatrophy improved the self-perceived quality of life and facial image as well as any depressive symptoms among patients with HIV/AIDS.
authors.affiliation: Plastic Surgery Department, University of Pernambuco, Recife, Brazil.
authors.forename: Rodrigo C S
authors.initials: RC
authors.lastname: Quintas
authors.forename: Emmanuel R
authors.initials: ER
authors.lastname: de França
authors.forename: Kátia C L
authors.initials: KC
authors.lastname: de Petribú
authors.forename: Ricardo A A
authors.initials: RA
authors.lastname: Ximenes
authors.forename: Lóren F F M
authors.initials: LF
authors.lastname: Quintas
authors.forename: Ernando L F
authors.initials: EL
authors.lastname: Cavalcanti
authors.forename: Marco A P
authors.initials: MA
authors.lastname: Kitamura
authors.forename: Kássia A A
authors.initials: KA
authors.lastname: Magalhães
authors.forename: Késsia C F
authors.initials: KC
authors.lastname: Paiva
authors.forename: Demócrito B Miranda
authors.initials: DB
authors.lastname: Filho
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000150:complications* / Q000188:drug therapy; D000328:Adult; D000368:Aged; D019380:Anti-HIV Agents / Q000627:therapeutic use; D003863:Depression / Q000523:psychology; D003879:Dermatologic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D004438:Ecchymosis / Q000139:chemically induced; D004487:Edema / Q000139:chemically induced; D005145:Face; D005260:Female; D039682:HIV-Associated Lipodystrophy Syndrome / Q000523:psychology* / Q000628:therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D019904:Polymethyl Methacrylate / Q000008:administration & dosage* / Q000009:adverse effects; D011569:Psychiatric Status Rating Scales; D011788:Quality of Life; D012871:Skin Diseases / Q000139:chemically induced; D011795:Surveys and Questionnaires; D055815:Young Adult
chemical_list: D019380:Anti-HIV Agents; D003879:Dermatologic Agents; D019904:Polymethyl Methacrylate